STOCK TITAN
  1. Home
  2. News
  3. IMTX

Immatics N.V - IMTX STOCK NEWS

Welcome to our dedicated news page for Immatics N.V (Ticker: IMTX), a resource for investors and traders seeking the latest updates and insights on Immatics N.V.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Immatics N.V's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Immatics N.V's position in the market.

News
Immatics Announces Full Year 2023 Financial Results and Corporate Update
Rhea-AI Summary
Immatics N.V. provided an update on their ACTengine® IMA203 GEN1 in melanoma, reporting a 50% confirmed objective response rate with a median duration of response not reached at a median follow-up of 14.4 months. They also announced plans for a Phase 2/3 trial in 2L+ melanoma in 2024 and upcoming data updates for other products. Financially, Immatics completed a $201.5 million public offering in January 2024, with cash and cash equivalents totaling $470.6 million as of December 31, 2023, projecting a cash runway into 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.89%
Tags
earnings
-
News
Immatics Announces Pricing of $175 Million Public Offering
Rhea-AI Summary
Immatics N.V. (IMTX) announced the pricing of an underwritten public offering of 15,925,000 ordinary shares at a public offering price of $11.00 per share, expected to raise approximately $175 million in gross proceeds. The offering is expected to close on January 22, 2024, and the underwriters have a 30-day option to purchase additional shares. Jefferies, BofA Securities, and Leerink Partners are acting as joint book-running managers for the offering. The press release emphasizes that the offering is being made only by means of a prospectus supplement and accompanying prospectus, and provides contact information for obtaining copies of the final prospectus supplement and the accompanying prospectus.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
offering
-
News
Immatics Announces Proposed Public Offering
Rhea-AI Summary
Immatics N.V. (IMTX) has announced the commencement of an underwritten public offering of its ordinary shares, led by Jefferies, BofA Securities, and Leerink Partners. The offering is subject to market conditions and other factors, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. A registration statement relating to the securities has been filed with the U.S. Securities and Exchange Commission (SEC) and was declared effective on August 9, 2021. The offering will be made only by means of a prospectus supplement and accompanying prospectus. This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
offering
News
DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing
Rhea-AI Summary
DISCO Pharmaceuticals, a specialist biotech company, has emerged from stealth with a transformative surfaceome discovery technology to identify new targets and develop first-in-class drugs for cancer treatment. The company has successfully raised seed financing of EUR 20 million and is backed by a world-leading investor syndicate. DISCO has completed the first-ever map of the surfaceome of Small Cell Lung Cancer and is developing proprietary antibody-based treatments for it. The company is also working on Microsatellite-Stable Colorectal Cancer and has a pipeline of further undisclosed programs. The experienced team, led by CEO Roman Thomas, includes leading biopharma executives Dieter Weinand and Carsten Reinhardt. The company's surfaceome mapping platform has the potential to transform oncology treatment options and improve outcomes for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.27%
Tags
none
-
News
Immatics Announces Third Quarter 2023 Financial Results and Business Update
Rhea-AI Summary
Immatics N.V. (NASDAQ: IMTX) reported positive clinical data on ACTengine® IMA203 GEN1 and GEN2 TCR-T monotherapies targeting PRAME. The company also announced a strategic collaboration with Moderna and received an equity investment from Bristol Myers Squibb. Immatics' cash position is strong, with a projected cash runway into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
earnings
-
News
Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial
Rhea-AI Summary
IMTX: Immatics N.V. to Host Conference Call and Webcast to Discuss Positive Interim Data from Ongoing Phase 1 Trial with ACTengine® IMA203 in Patients with Solid Cancers, Including Melanoma. Key highlights include 50% confirmed objective response rate in melanoma patients treated at recommended Phase 2 dose, ongoing responses at >15 months, and plans to enter registration-enabling Phase 2 trial in melanoma in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.92%
Tags
clinical trial
News
Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy
Rhea-AI Summary
Immatics' IMA203 TCR-T program receives RMAT designation from FDA CBER for multiple PRAME-expressing tumors, including melanoma and ovarian cancer. The designation enhances the company's efforts to accelerate the development of IMA203 and brings potential benefits for advanced-stage solid tumor patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
none
-
News
Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors
Rhea-AI Summary
Protalix BioTherapeutics appoints Eliot Richard Forster, Ph.D. as Chairman of the Board of Directors, effective September 14, 2023. Zeev Bronfeld to retire from the Board. Forster's extensive experience in the life sciences industry is expected to strengthen the company's research and development efforts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.48%
Tags
management
-
News
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
Rhea-AI Summary
Moderna and Immatics announce a strategic research and development collaboration to develop therapies for cancer patients. Immatics will receive $120 million upfront cash payment plus research funding. The collaboration will leverage Immatics' TCR platform with Moderna's mRNA technology and focus on bispecifics, cell therapy, and cancer vaccines. The collaboration also includes evaluating Immatics' IMA203 TCR-T therapy in combination with Moderna's PRAME mRNA-based cancer vaccine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
none
News
Immatics Announces Second Quarter 2023 Financial Results and Business Update
Rhea-AI Summary
Immatics N.V. has provided a business update and reported financial results for the quarter ended June 30, 2023. The interim clinical data for IMA203 monotherapy showed a 67% confirmed objective response rate (ORR) in Phase 1b dose expansion Cohort A. Bristol Myers Squibb exercised its first opt-in into the cell therapy collaboration and made a $35 million equity investment. The company's cash position is $377.7 million as of June 30, 2023, and the projected cash runway is late 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.93%
Tags
earnings
Stock IMTX logo
Immatics N.V

Nasdaq:IMTX

IMTX Rankings

#2399 Ranked by Market Cap
#4013 Ranked by Stock Gains
N/A Ranked by Dividends

IMTX Stock Data

1.09B
76.56M
25.69%
50.65%
8.65%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Germany
Tuebingen

About IMTX

immatics is a clinical-stage biopharmaceutical company active in the discovery and development of t-cell redirecting immunotherapies for the treatment of cancer. our transformative product candidates are - best in class - adoptive cell therapies and bispecific tcr molecules. these products are directed against tumor targets that have been identified and validated by immatics'​ proprietary and world-leading xpresident® technology. our mission is to bring the power of t-cell redirecting immunotherapies to cancer patients. quick facts - 150 team members - >100 targets covering 20 major solid and liquid tumors - about 80% of discovered targets are novel - 2 proprietary technology platforms - 8 proprietary development programs, thereof 2 in the clinic in 2017 - multiple partnered programs - raised more than $230m in cash in five financings read more about immatics on our homepage: https://immatics.com/ find us on twitter and xing: twitter: http://bit.ly/2dfbpre xing: http://bit.ly/2e1kkpv l